Results 241 to 250 of about 349,749 (268)

The Peptide PROTAC Modality: A New Strategy for Drug Discovery

MedComm, Volume 6, Issue 4, April 2025.
Peptide PROTAC is a bifunctional molecule generally composed of a target protein binding peptide (TBP), a linker peptide (LP), an E3 ligase binding peptide (EBP), and a delivery‐enhancing peptide (DEP), which can bind to the target protein (P) and E3 ligase (E3), inducing P to be labeled with ubiquitin (Ub) and subsequently recognized and degraded by ...
Youmin Zhu, Yu Dai, Yuncai Tian
wiley   +1 more source

Age-related changes in the immune system and challenges for the development of age-specific vaccines. [PDF]

Ann Med
Doherty TM, Weinberger B, Didierlaurent A, Lambert PH.   +3 more
europepmc   +1 more source

Recent Technologies for the Determination of SARS‐CoV‐2 in Wastewater

ChemistrySelect, Volume 10, Issue 13, April 4, 2025.
The integration of WBE with conventional techniques such as PCR, ELISA, LAMP and CRISPR; and electrochemical biosensors based on a variety of bioreceptors can be used as a large‐scale tool to monitor the spread of COVID‐19, especially in communities with limited resources worldwide.
Nolwazi T. Gazu, Aoife Morrin, Xolile Fuku, Bhekie B. Mamba, Usisipho Feleni   +4 more
wiley   +1 more source

Increasing Prevalence of Occult HBV Infection in Adults Vaccinated Against Hepatitis B at Birth. [PDF]

Vaccines (Basel)
Zhong G, Jiang ZH, Wang XY, Chen QY, Zhang LJ, Hu LP, Huang ML, Huang YB, Hu X, Zhang WW, Harrison TJ, Fang ZL.   +11 more
europepmc   +1 more source

Targeting Frequent Efferocytosis in Tumor Microenvironment is a New Direction for Cancer Treatment

Small Science, Volume 5, Issue 4, April 2025.
Phagocytosis of “apoptotic tumor cells”, known as efferocytosis, accelerates the formation of an immunosuppressive microenvironment, leading to the detriment of tumor therapy. Blocking this process represents one of the novel approaches for treating tumors.
Gangxing Zhu, Xinliang Wan, Wanyin Wu, Luyu Jia, Xiaoyan Yu, Handan Mo, Xi Wang, Qichun Zhou, Qing Tang, Sumei Wang   +9 more
wiley   +1 more source

Exploring Implications of Risk Communication Strategies in Diminishing Adversities of Misinformation and Disinformation Against Hepatitis Vaccination in Global South. [PDF]

Risk Manag Healthc Policy
Mehdi M, Raza SH, Yousaf M, Li B, Zaman U, Riaz S.   +5 more
europepmc   +1 more source

Risankizumab in Japanese patients with moderate‐to‐severe palmoplantar pustulosis: Results from the randomized, phase 3 JumPPP study

The Journal of Dermatology, Volume 52, Issue 4, Page 593-602, April 2025.
Abstract Palmoplantar pustulosis (PPP) is a chronic, debilitating skin disease of the palms and/or soles. We report the efficacy and safety of risankizumab (RZB), an interleukin 23 p19 inhibitor, from the JumPPP study (a phase 3, multicenter, randomized, placebo‐controlled, double‐blind study to evaluate RZB in adult Japanese sUbjects with Moderate‐to ...
Yukari Okubo, Masamoto Murakami, Satomi Kobayashi, Shigeyoshi Tsuji, Mitsumasa Kishimoto, Kimitoshi Ikeda, Maiko Jibiki, Ezequiel Neimark, Byron Padilla, Jie Shen, Sydney Peters, Tadashi Terui   +11 more
wiley   +1 more source

Hepatitis B Vaccine Nonresponse and Associated Risk Factors: Insights From a Cohort Study. [PDF]

J Trop Med
Hudu SA, Jimoh AO, Shinkafi SH, Tahir A, Alshrari AS, Umar MT, Yunusa A, Bello N, Abubakar N.   +8 more
europepmc   +1 more source

Origins of T‐cell‐mediated autoimmunity in acquired aplastic anaemia

British Journal of Haematology, Volume 206, Issue 4, Page 1035-1053, April 2025.
Acquired aplastic anaemia (AA) is an autoimmune bone marrow failure disease caused by a cytotoxic T‐cell–mediated attack on haematopoietic stem and progenitor cells (HSPCs). Despite significant progress in understanding T‐cell repertoire alterations in AA, the identification of specific pathogenic T cells remains elusive.
Aura Enache, Shannon A. Carty, Daria V. Babushok   +2 more
wiley   +1 more source